Fresh analysis indicates that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a prominent health publication points out that while obese individuals can lose about a fifth of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users buying such medications must be aware of the potential of quick rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting mass in about a year and a half.
Comparing Treatments
The study, which looked at dozens of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone generally have a more gradual creep back—perhaps 100 grams monthly—once they finish.
Explaining the Rapid Regain
Nutrition scientists believe the way of the injections is key to understanding the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is uncontrolled, making overeating far more likely."
An Ongoing Issue?
The NHS advise the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of relapse, the therapy might need to be ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
User Experiences
Users who have discontinued the jabs explain a intense return of cravings.
"It felt as if something activating and you become ravenous," recalled a patient.
This difficulty is worsened if patients have not established lasting dietary or behavioural modifications during treatment.
Significant Interest
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while these medications are effective tools for weight loss, they are not a permanent solution and long-term success likely depends on integrated lifestyle support.
